← Leaderboards
Vassilios James Bezzerides
Boston Children'S Hospital
$3,020,881
Attributed
$3,020,881
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $752.6K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,020,881 · 2
By mechanism
R01$2,170,056 · 1
K08$850,825 · 1
Top collaborators
No co-investigators on record.
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- William T Pu$35,812,679
- Jane W. Newburger$29,827,102
- Clifford J Woolf$42,375,557
- Bernhard Kuhn$9,305,831
- Ali Gholipour-Baboli$9,206,245
Others in their field
Other Emerging Leaders on “Phenotype”
- Leonard Freedman · Leidos Biomedical Research, Inc.$68,463,085
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$28,580,688
- Evan Z Macosko · Broad Institute, Inc.$28,218,682
- Badri N Vardarajan · University Of Miami School Of Medicine$23,982,327
Research focus
PhenotypeClinical PhenotypeInduced Pluripotent Stem CellMyocardialSodium ChannelVentricular ArrhythmiaFamilyHeart RhythmMediatingMutationRecurrenceSodiumAffectStructureElectrophysiology (Science)CalciumHeartCardiacArrhythmiaInsightCardiac MyocytesMouse ModelBostonClinically Relevant
Grant awards (8)
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia$752,579
R01 · FY2025 · HL · contact PI
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia$737,527
R01 · FY2024 · HL · contact PI
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia$679,950
R01 · FY2023 · HL · contact PI
Novel molecular therapies for CPVT$170,165
K08 · FY2022 · HL · contact PI
Novel molecular therapies for CPVT$170,165
K08 · FY2021 · HL · contact PI
Novel molecular therapies for CPVT$170,165
K08 · FY2020 · HL · contact PI
Novel molecular therapies for CPVT$170,165
K08 · FY2019 · HL · contact PI
Novel molecular therapies for CPVT$170,165
K08 · FY2018 · HL · contact PI